xCures

Three products turn scattered records into a timeline and checklists

The vendor lists Evidence Grade Data, Automated Patient History and Decision-Ready Checklists. Automated Patient History assembles records from several sources into a deduplicated, structured longitudinal timeline delivered as FHIR R4, with source documents linked. Each extracted element maps back to "the exact source document and page", according to the vendor. Checklists are configurable extractions for chart prep, care gaps, prior authorization, revenue cycle, utilization management, case review, coding and clinical documentation improvement.

Records come from national networks, EHRs, health information exchanges, QHINs and direct uploads, and no EHR is named. The providers and Automated Patient History pages offer a 30-minute demo and list no price.

Accuracy figures are retrospective vendor numbers

The vendor reports 99.7% combined accuracy across more than 200 comorbidity assessments. For colonoscopy dates it reports 97.5% positive predictive value and 98.6% sensitivity, and for cancer diagnosis details 98.7% and 99.4%. It labels these retrospective and says they do not guarantee future performance. Its volume claims are 1.5 million documents a day over a trailing 90-day average and more than 300 million records processed to date. The homepage shows logos including Caris, Veracyte, NeoGenomics and Exact Sciences, and the providers page quotes the CEO of Genome Medical.

HITRUST i1 is xCures's own, SOC 2 and ISO 27001 belong to AWS

The trust page says xCures operates as a business associate and is HIPAA compliant, and that it received HITRUST i1 certification in 2026. The company page body says e1 and its footer says i1. The SOC 2 Type 2 and ISO 27001:2022 attestations named on the trust page are AWS's, and xCures states no SOC 2 report of its own.

The Series B figures come from aggregators

xCures, Inc. is at 1901 Harrison Street, Oakland, California, and says it was founded in 2018. Aggregator profiles list Marty Tenenbaum and Jeff Shrager as founders of a spin-out from the non-profit Cancer Commons, with Mika Newton as CEO. They report a $46M Series B in June 2026 led by Innovius Capital, and the date and lead are unverified. A 2021 Series A of about $12.69M was led by Boehringer Ingelheim Venture Fund, with Vanedge Capital, Harmonix Fund and Metaplanet. Older aggregator totals conflict with these figures.

One paper describes the platform, and it is vendor-authored

"A Health Care Clinical Data Platform for Rapid Deployment of Artificial Intelligence and Machine Learning Algorithms for Cancer Care and Oncology Clinical Trials" (North Carolina Medical Journal, 2024) describes the xCures platform and is vendor-authored. A 2022 Cureus paper on virtual tumor boards in neuro-oncology reviews xCures as one of three boards and does not evaluate the engine. The vendor's research page lists 18 items. By title, two more look engine-related, a 2026 paper on validated data extraction from electronic health records with large language models and a 2023 paper on AI-augmented clinical decision support in a precision oncology registry, and their PubMed status is not confirmed.

The verdict

Two items stay open: xCures's own SOC 2 position, which the trust page gives only for AWS, and the Series B details, which come from aggregators.